



## **PIM Internet Requirements and Front Matter for HTRS 2021 Enduring Materials**

### ***Target Audience***

This activity is intended for physicians, nurses, and pharmacists engaged in the care of people with hemostatic and thrombotic disorders.

### ***Educational Objectives***

After completing this activity, the participant should be better able to:

#### Learning Objective for Pre-conference Sessions 1 and 2: “New Therapies”

At the close of this session, attendees will be able to:

- Discuss new treatment options available to patients with bleeding and clotting disorders
- Describe how new inhibitor treatments can affect laboratory test results
- Analyze how treatment of bleeding and clotting disorders can be tailored using specific therapies
- Explain the approach for gender affirming medication treatment for gender dysphoria/incongruence.
- Describe the potential adverse reactions of estrogen/testosterone treatment and develop strategies to minimize risk
- Explain the relationship between trauma, behavior, and health outcomes.
- Develop strategies that promote the implementation of trauma informed care in their practice

#### Learning Objectives for Scientific Session 1: “The Future of Hemophilia Therapeutics: Substitution or Gene Therapy?” Debate

At the close of this session, attendees will be able to:

- Explain the current state of development of gene therapy for hemophilia.
- Compare and contrast the advantages and disadvantages of protein replacement therapy and gene therapy.
- Describe the safety profiles of protein replacement therapy and gene therapy.

#### Learning Objective for Scientific Session 2: State-of-the-Art Lecture and COVID-19

At the close of this session, attendees will be able to describe the current state of clinical, translational, and basic scientific studies investigating thrombotic and bleeding complications associated with SARS-CoV-2 infection

## Learning Objectives for Scientific Session 3 “Bench, Clinic, and Everything In-Between: Platelet Transfusion”

### Session 3A: “Platelets”

At the close of this session, attendees will be able to:

- Describe platelet transfusion practices in the REDS-III pediatric cohort
- Discuss whether the pathogen reduction process might impact antibody mediated platelet refractoriness.
- Analyze data from murine model to determine whether platelets can serve as adjuvants to recipient RBC alloantibody responses

### Session 3B: “Sickle Cell-Associated Thrombosis”

At the close of this session, attendees will be able to describe ongoing clinical, translational, and biochemical studies investigating sickle-cell associate thrombosis.

### Session 3-C: “Post-Thrombotic Syndrome”

At the close of this session, attendees will be able to:

- Explain the importance of the post-thrombotic syndrome (PTS) as a complication of deep venous thrombosis
- Summarize risk factors and prevention and management strategies for PTS
- Define and discuss the concept of post-pulmonary embolism syndrome

### Learning Objective for Oral Abstract Sessions

At the close of these sessions, attendees will be able to discuss emerging topics and research in the field of hemostasis and thrombosis, based on submitted abstracts.

### Learning Objective for Poster Presentation Sessions

At the close of these sessions, attendees will be able to discuss emerging topics and research in the field of hemostasis and thrombosis, based on submitted abstracts.

### ***Faculty***

Please refer to the [Presenters](#) page for a list of presenters

### ***Joint Accreditation Statement***



JOINTLY ACCREDITED PROVIDER™  
INTERPROFESSIONAL CONTINUING EDUCATION

In support of improving patient care, this activity has been planned and implemented by the Postgraduate Institute for Medicine and The Hemostasis and Thrombosis Research Society. Postgraduate Institute for Medicine is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for

Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

***Physician Continuing Medical Education***

The Postgraduate Institute for Medicine designates this enduring material for a maximum of 14.5 *AMA PRA Category 1 Credit(s)*<sup>TM</sup>. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

***Continuing Pharmacy Education***

Postgraduate Institute for Medicine designates this continuing education activity for 14.5 contact hour(s) (0.145 CEUs) of the Accreditation Council for Pharmacy Education.

(Universal Activity Number - JA4008162-9999-21-2465-H01-P)

Type of Activity: Knowledge

Hardware/Software Requirements

Internet browser and an internet connection with a minimum bandwidth of 500 kbps

Policy on Privacy and Confidentiality

Please see final activity for the policy on privacy and confidentiality that relates to this internet activity.

***Continuing Nursing Education***

The maximum number of hours awarded for this Continuing Nursing Education activity is 14.5 contact hours. Designated for 3.5 contact hours of pharmacotherapy credit for Advanced Practice Registered Nurses.

***Disclosure of Conflicts of Interest***

Postgraduate Institute for Medicine (PIM) requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose any real or apparent conflict of interest (COI) they may have as related to the content of this activity. All identified COI are thoroughly vetted and resolved according to PIM policy. PIM is committed to providing its learners with high quality activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of a commercial interest.

***Faculty***

Hanny Al-Samkari, MD

Dr. Al-Samkari has nothing to disclose.

Morey A. Blinder, MD

Dr. Blinder has nothing to disclose.

Michael U. Callaghan, MD

Consulting fees from Bayer Healthcare, BioMarin, Catalyst BioSciences, HEMA Biologics, Kedrion, Pfizer, Inc, Sanofi, Spark Therapeutics, Takeda, uniQure  
Grant funding from Pfizer Inc, Genentech/ Roche

Robert A. Campbell, PhD

Dr. Campbell has nothing to disclose.

Rachael F. Grace, MD, MMSc  
Consulting fees from Dova  
Grant funding from Novartis Pharmaceutical

Jeanne Hendrickson, MD  
Dr. Hendrickson has nothing to disclose

Peter Henke, MD  
Consulting fees from Bayer

Farouc Jaffer, MD, PhD  
Consulting fees from Boston Scientific Corporation, Magenta Medical, Siemens  
Speaker fees from Asahi Intecc, Biotronik  
Stockholder with Intravascular Imaging Incorporated  
Royalties from Massachusetts General Hospital  
Research Support from Canon, Shockwave, Siemens, Teleflex

Susan Kahn, MD, MSc  
Dr. Kahn has nothing to disclose.

Riten Kumar, MD, MSc  
Dr. Kumar has nothing to disclose.

Roger J. Lewis, MD, PhD  
Salary from Berry Consultants, LLC

Kellie Machlus, PhD  
Dr. Machlus has nothing to disclose.

Jim Munn, MS, BS, BSN, RN-BC  
Consulting fees from Bayer Healthcare, CSL Behring, Genentech, Novo Nordisk,  
Octapharma USA, Sanofi, Takeda, uniQure

Darcy Phelan, MSN, ANP-BC  
Ms Phelan has nothing to disclose.

Meredith Russell, MSN, AC-CPNP  
Ms Russell has nothing to disclose.

Denise Sabatino, PhD  
Consulting fees from Poseida Therapeutics  
Royalties from Spark Therapeutics

Erica Sparkenbaugh, PhD  
Dr. Sparkenbaugh has nothing to disclose.

Amanda Stahl, LICSW  
Ms Stahl has nothing to disclose.

Huanghe Yang, PhD  
Dr. Yang has nothing to disclose.

### *Planners and Managers*

The PIM planners and managers have nothing to disclose. The HTRS planners and managers have nothing to disclose.

### ***Method of Participation and Request for Credit***

A statement of credit will be issued only upon receipt of a completed activity evaluation form and will be emailed to you within three weeks. You will receive your certificate from [CEcertificate@pimed.com](mailto:CEcertificate@pimed.com). If you have questions regarding the receipt of your emailed certificate, please contact PIM via email at [inquiries@pimed.com](mailto:inquiries@pimed.com).

For Pharmacists: Upon receipt of the completed activity evaluation form, you will receive an email from [CEcertificate@pimed.com](mailto:CEcertificate@pimed.com) within 3 weeks with a link and directions to submit your credit to the NABP CPE Monitor Service.

### ***Request for Credit***

If you wish to receive acknowledgment for completing this activity, please complete the evaluation on [www.cmeuniversity.com](http://www.cmeuniversity.com).

- 1) Login or Create a New Account (will take less than 1 minute)
  - a) If you receive a message when creating a new account that “the email you entered is already in use”, please click the [Forgot my Username or Password](#) link to have your Username and Password sent to you via email
  - b) After logging in, you may be asked to verify/update your information; after doing so, click Save at the bottom of the page
- 2) Type in **15954** at the top of the page, “Find Post-Test/Evaluation by Course”, and click enter
- 3) Click on the activity title when it appears
- 4) Choose the type of credit you desire
- 5) Complete the online Evaluation
- 6) Receive an immediate CME/CE Certificate to download and/or print for your files

For Pharmacists: Upon completion of the online evaluation, your credit will be submitted to CPE Monitor. *Pharmacists have up to thirty (30) days to complete the evaluation and claim credit. Please check your NABP account within thirty (30) days to make sure the credit has posted.*

If you have questions regarding the certification of this activity, please contact PIM via email at [inquiries@pimed.com](mailto:inquiries@pimed.com).

### ***Media***

Internet

### ***Computer System Requirements***

Internet browser and an internet connection with a minimum bandwidth of 500 kbps

### ***Disclosure of Unlabeled Use***

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications. The opinions expressed in the educational activity are those of the faculty and do not necessarily

represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

*Disclaimer*

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient's conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer's product information, and comparison with recommendations of other authorities.